Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews recent advances in the synthesis of oxasteroids and reports no new experimental results.

This review discusses biochemical studies on 5 alpha-reductase and its inhibitors, comparing IC50 and Ki values for various compounds, but reports no new experimental results.

In this study, a treatment regimen combining cyproterone acetate and ethinyl estradiol significantly improved acne and seborrhoea in most women after three months, but had varied effects on hirsutism and alopecia.

This study compared hormone levels between oriental and Caucasian men, finding that while oriental men share similar plasma testosterone levels, their 17-oxosteroid excretion is lower, which may influence beard growth differences.

Validated method reliably measures finasteride in tablets using liquid chromatography.

This paper describes recent advancements in the synthesis of thiasteroids but reports no new experimental results, noting that introducing heteroatoms in steroidal structures has potential biological effects.

This review discusses the development and selectivity of 5 alpha-reductase inhibitors, particularly non-steroidal ones, and reports no new clinical trial results.

This study found that finasteride significantly alters urinary steroid profiles, complicating the detection of steroid abuse in doping-control analysis by potentially causing false-negative results.

This review discusses the potential uses of 5α-reductase inhibitors for conditions ranging from benign prostatic hyperplasia to skin disorders like acne and male pattern baldness, but it reports no new clinical results.

This study found that during dialysis, lower plasma-potassium levels were associated with hyperglycemia, suggesting potassium correction is vital when using glucose-rich dialysate.

This study found that 4-MA is a potent inhibitor of testosterone 5α-reductase in human tissues, promising potential for treating androgen-dependent skin conditions like male pattern baldness.

This study explains finasteride's high potency and specificity as a mechanism-based inhibitor for treating benign prostatic hyperplasia by detailing its interaction with human type 2 steroid 5α-reductase.

This review discusses the potential role of steroid 5α-reductase inhibitors in treating neuropsychiatric disorders related to dopaminergic hyperreactivity but reports no new clinical results.

This study suggests that finasteride-loaded liquid crystalline nanoparticles could be a viable alternative to oral administration for treating androgenetic alopecia due to their controlled release and skin permeation properties.

This study examined different polymersome systems for topical finasteride delivery and found that chitosan-decorated C7 polymersomes may enhance skin retention and provide controlled drug release compared to non-decorated systems in laboratory settings.

This study developed a fully automated HPLC method for accurately quantifying finasteride in human plasma, achieving a detection limit of 1 ng/ml with validated application in pharmacokinetic studies.

Finasteride remains stable for two years with proper storage.

This study observed that most hirsute patients on combined cyproterone acetate and 'Diane' therapy experienced a reduction in hair growth, with hair becoming softer, thinner, and lighter in color over 12 months.

This review discusses the structure and function of steroid nuclear receptors, particularly focusing on androgen receptor dysregulation in prostate cancer and androgen insensitivity syndromes, without reporting new experimental results.

This study developed and validated an HPLC method for detecting a novel 5α-reductase inhibitor in human plasma, supporting its pharmacokinetic evaluation at low doses.

In this study, 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides were synthesized and evaluated in vitro as potential 5 alpha-reductase inhibitors and antiandrogens.

This study found that injectable finasteride microspheres provided a sustained drug release with a minimal initial burst in albino rabbits compared to oral suspension.

New method effectively analyzes finasteride and its stability.

The document explains different hair and scalp conditions, including common hair loss after pregnancy or illness, drug-induced hair loss, hereditary excessive hair growth, patterned baldness, autoimmune hair loss, and permanent loss due to skin disease, with generally limited treatment options.

This study reported that while no synthesized compounds surpassed finasteride in 5α-reductase inhibitory activity, certain 4-azasteroid-2-oximes exhibited notable inhibition.

This study found that finasteride decreased plasma dihydrotestosterone levels and altered steroid metabolism, similar to the profile of male pseudohermaphrodites with inherited 5a-reductase deficiency.

This review highlights that idiopathic hirsutism is characterized by local hyperandrogenization affecting hair growth, without other signs of hyperandrogenism, and shows no new results; racial differences in prevalence are noted but not in androgenic steroids.

This study found that finasteride competitively inhibits the enzyme AKR1D1 with low micromolar affinity but does not act as a mechanism-based inactivator.

This review discusses the potential of 4-azasteroids as 5α-reductase inhibitors for treating hirsutism, reporting their promising effects in animal studies but noting no clinical trials have been conducted yet.

This review discusses androgen manipulation strategies for conditions like benign prostatic hyperplasia and prostatic carcinoma but reports no new clinical results.